Montelukast
- Generic Name
- Montelukast
- Brand Names
- Singulair
- Drug Type
- Small Molecule
- Chemical Formula
- C35H36ClNO3S
- CAS Number
- 158966-92-8
- Unique Ingredient Identifier
- MHM278SD3E
- Background
Montelukast was first approved for clinical use by the US FDA in 1998 as Merck's brand name Singulair. The medication is a member of the leukotriene receptor antagonist (LTRA) category of drugs. Although capable of demonstrating effectiveness, the use of such LTRAs like montelukast is typically in addition to or complementary with the use of inhaled corticos...
- Indication
Montelukast is indicated for:
...
- Associated Conditions
- Asthma, Exercise-Induced Bronchospasm, Perennial Allergic Rhinitis (PAR), Seasonal Allergic Rhinitis
- Associated Therapies
- -
Repurposed Use of Allergic Rhinitis and Allergic Asthma Drug to Reduce Vertigo and Hearing Loss in Meniere's Disease
- Conditions
- Interventions
- First Posted Date
- 2021-03-24
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- House Ear Institute
- Target Recruit Count
- 40
- Registration Number
- NCT04815187
- Locations
- ๐บ๐ธ
House Ear Clinic, Los Angeles, California, United States
๐บ๐ธHouse Institute Foundation, Los Angeles, California, United States
Montelukast - a Treatment Choice for COVID-19
- Conditions
- Interventions
- First Posted Date
- 2021-01-19
- Last Posted Date
- 2021-01-19
- Lead Sponsor
- University of Sargodha
- Target Recruit Count
- 150
- Registration Number
- NCT04714515
- Locations
- ๐จ๐ณ
Department of Critical Care Medicine, Shanghai General Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, China, Shanghai, China
๐ต๐ฐShaukat Khanum Memorial Cancer Hospital & Research Centre, Johar Town, Lahore, Pakistan, Lahore, Punjab, Pakistan
Efficacy of Montelukast in Mild-moderate Respiratory Symptoms in Patients With Long-COVID-19:
- First Posted Date
- 2021-01-05
- Last Posted Date
- 2024-07-03
- Target Recruit Count
- 86
- Registration Number
- NCT04695704
- Locations
- ๐ช๐ธ
Primaty health Center Corbera, Corbera De Llobregat, Barcelona, Spain
๐ช๐ธPrimary Health Center Jaume Soler, Cornellร De Llobregat, Barcelona, Spain
๐ช๐ธPrimary Health Center Camps Blancs, Sant Boi De Llobregat, Barcelona, Spain
Effect of Montelukast in Preventing Dengue With Warning Signs in Dengue Patients
- Conditions
- Interventions
- First Posted Date
- 2020-12-17
- Last Posted Date
- 2023-07-18
- Lead Sponsor
- Phramongkutklao College of Medicine and Hospital
- Target Recruit Count
- 358
- Registration Number
- NCT04673422
- Locations
- ๐น๐ญ
Ananda Mahidol Hospital, Lopburi, Thailand
๐น๐ญFort Suranari Hospital, Nakhon Ratchasima, Thailand
๐น๐ญPhramongkutklao Hospital, Bangkok, Thailand
MOntelukast as a Potential CHondroprotective Treatment Following Anterior Cruciate Ligament Reconstruction (MOCHA Trial)
- Conditions
- Interventions
- First Posted Date
- 2020-10-01
- Last Posted Date
- 2024-04-30
- Lead Sponsor
- Austin V Stone
- Target Recruit Count
- 30
- Registration Number
- NCT04572256
- Locations
- ๐บ๐ธ
UK Healthcare at Turfland, Lexington, Kentucky, United States
Comparison of Montelukast and Azelastine in Treatment of Moderate to Severe Allergic Rhinitis
- Conditions
- Interventions
- First Posted Date
- 2020-09-24
- Last Posted Date
- 2020-09-25
- Lead Sponsor
- Shiraz University of Medical Sciences
- Target Recruit Count
- 66
- Registration Number
- NCT04561687
- Locations
- ๐ฎ๐ท
Shiraz University of Medical Science, Shiraz, Iran, Islamic Republic of
Efficacy and Safety of Montelukast in Non Alcoholic Steatohepatitis (NASH)
- First Posted Date
- 2020-09-03
- Last Posted Date
- 2020-09-03
- Lead Sponsor
- Tanta University
- Target Recruit Count
- 44
- Registration Number
- NCT04537780
- Locations
- ๐ช๐ฌ
Dr. Tarek Mohamed Mostafa, Tanta, El-Gharbia, Egypt
SMILES: Study of Montelukast in Sickle Cell Disease
- Conditions
- Interventions
- First Posted Date
- 2020-04-17
- Last Posted Date
- 2023-11-01
- Target Recruit Count
- 200
- Registration Number
- NCT04351698
- Locations
- ๐ฌ๐ง
Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom
A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma
- First Posted Date
- 2020-02-13
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 306
- Registration Number
- NCT04268498
- Locations
- ๐บ๐ธ
University of Miami, Miami, Florida, United States
๐บ๐ธMD Anderson Cancer Center, Houston, Texas, United States
๐บ๐ธMoffitt Cancer Center, Tampa, Florida, United States
Montelukast Therapy on Alzheimer's Disease
- First Posted Date
- 2019-06-19
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- Emory University
- Target Recruit Count
- 32
- Registration Number
- NCT03991988
- Locations
- ๐บ๐ธ
Executive Park, Atlanta, Georgia, United States
๐บ๐ธWesley Woods, Atlanta, Georgia, United States
๐บ๐ธEmory Clinic, Atlanta, Georgia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.